OTC Drug Facts Panel Compliance: The Labeling Errors That Trigger FDA Warning Letters

FDA warning letters for OTC drug labeling violations rarely come as a surprise to the agency — but they almost always catch manufacturers off guard. The Drug Facts panel has been a regulatory requirement since August 2002, yet 21 CFR 201.66 remains one of the most consistently misapplied regulations in the OTC drug space. After years of consulting on FDA compliance, I still see the same errors resurface: wrong type sizes, missing warning subsections, and active ingredient formats that technically violate the regulation even when the underlying product is perfectly safe.

The US over-the-counter drug market is large — estimated at over $47 billion in annual retail sales — and it’s served by thousands of manufacturers ranging from Fortune 500 pharmaceutical companies to small contract operations handling private-label products for retailers. Across that spectrum, Drug Facts panel errors are surprisingly democratic. They show up in startup brands and established product lines alike.

Here’s what the regulation actually requires, where companies keep getting it wrong, and how to conduct a credible self-audit before FDA does it for you.

What 21 CFR 201.66 Actually Requires — and What Most Teams Miss

The Drug Facts format isn’t optional, and neither is its sequence. Section 201.66(c) specifies the required headings in exact order: Active Ingredient(s), Purpose, Uses, Warnings, Directions, Other Information (if included), Inactive Ingredients, and Questions (if included). Deviation from that order — even if all the content is present — constitutes a labeling violation under Section 502(a) of the FD&C Act, which defines misbranded drugs. “Close enough” isn’t a legal standard FDA applies to labeling format.

The type size requirements are where I see the most routine failures. The “Drug Facts” header must appear in at least 14-point bold type. Most body content within the panel requires a minimum of 6-point type, but that minimum applies only when label area constraints genuinely prevent larger type — not as a baseline target. FDA inspectors have flagged labels where manufacturers squeezed text to 6-point across the entire panel when the package had sufficient surface area to accommodate 8-point. The regulation at 201.66(d) is clear: larger type is required when the label area allows it. Defaulting to the minimum is both a regulatory misread and a readability failure that won’t play well in a response to a Warning Letter.

There’s also the hairline rule requirement. Each Drug Facts section must be separated by a horizontal hairline rule. This sounds minor. It isn’t. FDA has issued warning letters specifically citing absent or inconsistent hairline rules as part of broader labeling deficiency findings. When an inspector is reviewing a label against a checklist, every element counts — and “it’s just a line” is not a persuasive response to an FDA observation.

The Five Violation Patterns That Show Up Most Often

OTC drug labeling violations tend to cluster around five patterns. Knowing them before an inspection is far more useful than learning them from a Warning Letter.

1. Incomplete warnings section. The warnings heading in 21 CFR 201.66(c)(5) contains multiple required subsections: “Do not use,” “Ask a doctor before use if you have,” “Ask a doctor or pharmacist before use if you are,” “When using this product,” “Stop use and ask a doctor if,” “If pregnant or breast-feeding,” and “Keep out of reach of children.” That last phrase is required for virtually every OTC drug without exception. FDA has cited products where the phrase was present but buried in a format that didn’t comply with the prescribed subsection structure. The phrase alone isn’t enough — it must appear as a distinct, properly labeled warning subsection.

2. Claims that go outside the approved monograph. OTC drugs marketed under FDA monographs — for categories like antacids, antihistamines, and external analgesics under 21 CFR Parts 330–358 — must restrict their use claims to the exact terms approved in the relevant Final Monograph. Manufacturers frequently add efficacy language drawn from consumer research that sounds reasonable on the surface but isn’t part of the monograph text. “Calms occasional digestive discomfort” might seem like a benign variant of “antacid,” but if it doesn’t map precisely to the permitted labeling language, it’s a violation. FDA’s enforcement posture here has been consistent for two decades: the monograph is the ceiling, not a floor.

3. Active ingredient listing errors. Each active ingredient must be listed with its established name and quantity per dosage unit. The “established name” is defined under 21 CFR 201.10 — it’s not the brand name, not the trade name, and not a synonym the marketing team prefers. A label listing “acetaminophen (APAP)” in the active ingredient field when the established name is simply “acetaminophen” is technically deficient. These feel like drafting oversights, and they are — but they’re exactly the kind FDA reviewers flag during systematic label review.

4. Supplement labeling that crosses into unapproved drug territory. A product sold as a dietary supplement under DSHEA using structure/function claims can cross into unapproved drug status if its labeling — including its website and advertising — explicitly or implicitly claims to diagnose, cure, treat, or prevent a disease. “Supports healthy blood sugar levels” is a permissible structure/function claim. “Lowers blood glucose in diabetic patients” is a drug claim. FDA considers the totality of the labeling. The website counts. Social posts count. And the volume of warning letters targeting supplement-to-drug misbranding has increased substantially over the past several years, with FDA explicitly referencing company websites as evidence in multiple enforcement actions.

5. Incomplete foreign-language labeling. If a manufacturer voluntarily includes labeling in a language other than English, 21 CFR 201.15 requires that the non-English text be a complete translation of the Drug Facts panel — not a summary or a marketing-edited version. Products targeting bilingual markets often include Spanish-language text that captures the essentials from a consumer experience perspective but omits warning subsections considered secondary. That’s a violation regardless of intent. If you include it, it has to be complete.

How FDA Detects Violations — and What the Enforcement Sequence Looks Like

FDA’s OTC drug labeling enforcement comes from multiple channels. Routine market surveillance sampling, consumer complaints, competitive complaints from industry, and coordination between CDER and CFSAN all generate leads. Post-DSCSA, there’s also more systematic supply chain documentation that can surface discrepancies between what’s on file and what’s actually in market.

When FDA identifies a potential violation, the typical sequence begins with an informal request for voluntary corrective action. If that doesn’t resolve it — or if the violation is significant enough to bypass informal resolution — FDA issues a Warning Letter. Warning Letters are public documents posted to FDA’s searchable database, often within days of issuance. Regulatory intelligence services and trade press pick them up within hours. The reputational consequences frequently exceed the operational cost of correcting the label.

Failure to respond adequately to a Warning Letter can escalate to seizure, injunction, or consent decree. For smaller manufacturers, the cost of operating under a consent decree — which typically requires third-party auditing, process remediation, written commitments, and sustained FDA oversight — can be existential. We’ve advised companies through consent decree responses, and the operational overhead is substantial even for well-resourced organizations. The better outcome, by far, is catching the violation internally before it triggers agency action.

Auditing Your OTC Labeling Before FDA Does

The most effective thing a manufacturer can do before an FDA inspection is perform a structured labeling compliance review against the actual text of 21 CFR 201.66 — not against an internal checklist developed years ago by someone who may have paraphrased the regulation.

Start with the physical label. Pull the finished package from your production line — not the master label file from your document management system, not a PDF proof. FDA inspects what’s in the market. Measure the type size on the physical label with a type gauge or calibrated ruler. Confirm that every section appears in the correct regulatory sequence. Verify hairline rules between sections. Confirm the “Drug Facts” header meets the 14-point minimum. If your packaging team did a redesign in the last two years for aesthetic reasons, redo this check — design updates are a common entry point for compliance drift.

Then audit the content layer. Map every use claim, word for word, against the applicable monograph language. If your product isn’t monograph-eligible and isn’t covered by an approved New Drug Application, it may not be legally marketable as an OTC drug regardless of how the Drug Facts panel is formatted. Confirm that every warning subsection required for your product category is present, correctly sequenced, and formatted as a distinct subsection — not run together with adjacent content.

Finally, examine your full labeling ecosystem. FDA’s definition of “labeling” in 21 U.S.C. 321(m) includes all written, printed, or graphic matter accompanying the article, which courts and FDA have consistently interpreted to include product websites, promotional inserts, and digital advertising. If your website makes claims your physical label doesn’t support — or vice versa — that inconsistency creates real enforcement exposure. Pull your top five Google search results for your product and read the copy like an FDA investigator would.

If your last labeling review happened more than 18 months ago, or coincided with a packaging redesign where compliance was secondary to aesthetics, it’s worth engaging regulatory compliance consulting support to pressure-test your current labeling against the current regulation text. This is especially true if your product category has had recent monograph updates — FDA has finalized several OTC monographs in recent years under the CARES Act framework, and any product marketed under a superseded interim final monograph needs a fresh review.

The Drug Facts panel has been around long enough that there’s no excuse for getting it materially wrong. But the regulations are specific, the enforcement record is public, and FDA’s appetite for OTC labeling oversight hasn’t diminished. Catching the error yourself costs a fraction of what a Warning Letter response will cost you — let alone a consent decree.

Written by Sam Sammane, Founder & CEO, Aurora TIC | Founder, Qalitex Group. Learn more about our team

Talk to our compliance consultants about a proactive OTC labeling review before your next FDA inspection. Contact us

Related from our network

• Third-Party Lab Testing for OTC Ingredients and Finished Products — Qalitex Laboratories provides ISO 17025-accredited testing for OTC drug raw materials and finished products, including identity verification and potency confirmation.
• Pharmaceutical GMP and Quality System Consulting for Canadian Manufacturers — Androxa supports Canadian drug manufacturers seeking Health Canada GMP compliance, including labeling alignment with Canadian regulatory requirements.